IP Verse

Methods And Kits For The Molecular Subtyping Of Tumors - EP2959021

The patent EP2959021 was granted to Biontech Diagnostics on Aug 8, 2018. The application was originally filed on Aug 19, 2014 under application number EP14755642A. The patent is currently recorded with a legal status of "Revoked".

EP2959021

BIONTECH DIAGNOSTICS
Application Number
EP14755642A
Filing Date
Aug 19, 2014
Status
Revoked
May 26, 2023
Grant Date
Aug 8, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

JAMES POOLEMay 7, 2019CARPMAELS & RANSFORDADMISSIBLE

Patent Citations (3) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
EXAMINATIONWO2009158143
INTERNATIONAL-SEARCH-REPORTWO2010076322
INTERNATIONAL-SEARCH-REPORTWO2013082440

Non-Patent Literature (NPL) Citations (24) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- Aigner et al., "Molekulare Subtypisierung auf mRNA Basis prädiziert Therapieansprechen und Ueberleben nach neoadjuvanter Chemotherapie", Thieme, Thieme, (20120705), Database accession no. 9-A2, URL: Senologie - Zeitschrift für Mammadiagnostik und -therapie 2012-
EXAMINATION- GOLDHIRSCH A ET AL, "Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.", ANNALS OF ONCOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY SEP 2013, (201309), vol. 24, no. 9, ISSN 1569-8041, pages 2206 - 2223-
EXAMINATION- LAIBLE MARK ET AL, "Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.", BMC CANCER 2016, (2016), vol. 16, ISSN 1471-2407, page 398-
EXAMINATION- SINN P ET AL, "Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility.", GEBURTSHILFE UND FRAUENHEILKUNDE SEP 2013, (201309), vol. 73, no. 9, ISSN 0016-5751, pages 932 - 940-
EXAMINATION- S Sahebjam ET AL, "Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score", British Journal of Cancer, GB, (20111004), vol. 105, no. 9, doi:10.1038/bjc.2011.402, ISSN 0007-0920, pages 1342 - 1345, XP055419009
EXAMINATION- PAIK S ET AL, "A MULTIGENE ASSAY TO PREDICT RECURRENCE OF TAMOXIFEN-TREATED, NODE-NEGATIVE BREAST CANCER", NEW ENGLAND JOURNAL OF MEDICINE, THE -, MASSACHUSETTS MEDICAL SOCIETY, US, (20041230), vol. 351, no. 27, doi:10.1056/NEJMOA041588, ISSN 1533-4406, pages 2817 - 2826, XP008043033
EXAMINATION- A. Goldhirsch ET AL, "Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011", Annals of Oncology, (20110627), vol. 22, no. 8, doi:10.1093/annonc/mdr304, ISSN 0923-7534, pages 1736 - 1747, XP055164503
EXAMINATION- M. C. U. Cheang ET AL, "Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer", JNCI Journal of the National Cancer Institute, (20090520), vol. 101, no. 10, doi:10.1093/jnci/djp082, ISSN 0027-8874, pages 736 - 750, XP055066172
EXAMINATION- Lyndsay Harris ET AL, "American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer", JOURNAL OF CLINICAL ONCOLOGY, US, (20071120), vol. 25, no. 33, doi:10.1200/JCO.2007.14.2364, ISSN 0732-183X, pages 5287 - 5312, XP055419000
OPPOSITION- Anonymous, "Deutsche Gesellschaft für Senologie 32. Jahrestagung - Programm...", KelCon GmbH, (20120705), pages 3 - 93, XP055650360-
OPPOSITION- Anonymous, "Posters1 st", Internet Archive Wayback Machine, (20081208), URL: https://web.archive.org/web/2008*/http://posters1st.com-
OPPOSITION- Dr. Ralph M. Wirtz, "MammaTYPER. Ki67 mRNA Einzelgenmessung prädiziert Ansprechen auf Chemotherapie", Powerpoint presentation, (20120721), pages 1 - 16, XP055590966-
OPPOSITION- PAIK, "A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer", The New England Journal of Medicine, (20041230), vol. 351, no. 27, pages 2817 - 2826, XP002578486-
OPPOSITION- "PREDICTING RESPONSE TO A HER DIMERISATION INHIBITOR BASED ON LOW HER3 EXPRESSION", Nucleotide, Database accession no. FW417868, URL: ncbi, XP055590958-
OPPOSITION- SKARLOS P. et al, "Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial", Cancer Chemotherapy and Pharmacology, (20120909), vol. 69, no. 2, pages 533 - 546, XP035006924
OPPOSITION- VON MINCKWITZ, "Selecting the neoadjuvant treatment by molecular subtype: How to maximize the benefit?", The Breast, (20130201), vol. 22, no. Suppl 2, pages S149 - S151, XP055590960
OPPOSITION- DIETRICH W. et al, "Testosterone dependent androgen receptor stabilization and activation of cell proliferation in primary human myometrial microvascular endothelial cells", Fertility and Sterility, (20111108), vol. 95, no. 4, pages 1247 - 1255.e2, XP028169804
OPPOSITION- Aigner J. et al, "Molekulare Subtypisierung auf mRNA Basis pradiziert Therapieansprechen und Uberleben nach neoadjuvanter Chemotherapie (9-A2)", Poster - Senologie - Zeitschrift für Mammadiagnostik und Therapie, (20120705), XP055590914
OPPOSITION- AIGNER, "Molekulare Subtypisierung auf mRNA Basis pradiziert Therapieansprechen und Uberleben nach neoadjuvanter Chemotherapie (9-A2)", SENOLOGIE-ZEITSCHRIFT FUR MAMMADIAGNOSTIK UND-THERAPIE, (20120705), XP002785152
OPPOSITION- SINN, "Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility", Geburtsh Frauenheilk, (20130900), vol. 73, no. 9, pages 932 - 940, XP055510437
OPPOSITION- SCHNEEWEISS A. et al, "A randomized phase II trial of doxorubicin pluspemetrexed followed by docetaxel versus doxorubicinplus cyclophosphamide followed by docetaxel asneoadjuvant treatment of early breast cancer", Annals of Oncology, (20110301), vol. 22, no. 3, pages 609 - 617, XP055590947
OPPOSITION- GOLDHIRSCH, "Strategies for subtypes-dealing with the diversity ofbreast cancer: highlights of the St Gallen InternationalExpert Consensus on the Primary Therapy of EarlyBreast Cancer 2011", Annals of Oncology, (20110627), vol. 22, no. 8, pages 1736 - 1747, XP055164503
OPPOSITION- PARKER J. et al, "Supervised risk predictor of breast cancer based on intrinsic subtypes", Journal of Clinical Oncology, (20090310), vol. 27, no. 8, pages 1160 - 1167, XP009124878
OPPOSITION- GONCALVES, "Using Multigene Tests to Select Treatment for Early--Stage Breast Cancer", Journal of the National Comprehensive Cancer Network, (20130200), vol. 11, no. 2, pages 174 - 182, XP055590954

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents